On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of ...

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for ...

While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also ...

The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...

Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the ...

In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, ...

Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines ...

Over one-third of BioSpace LinkedIn poll respondents have done free work while interviewing for jobs. A recruiting expert and ...

Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences ...

Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One ...